Derek De-Rui Huang|James Chih-Hsin Yang - JoVE Visualize

Showing results (111-120 of 259) with videos related to

Pageof 26

Sort By:

European Journal of Cancer (Oxford, England : 1990)|June 24, 2014

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trialJames Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, et al.

The Oncologist|May 17, 2017

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line GefitinibZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.

European Journal of Cancer (Oxford, England : 1990)|July 7, 2019

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patientsZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.

Cancer Treatment Reviews|January 3, 2026

Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Seng Wee Cheo, Molly S C Li, Derek De-Rui Huang, et al.

Science Translational Medicine|December 9, 2016

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastasesZhenfan Yang, Qiuli Guo, Yingchun Wang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2018

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung CancerChee Khoon Lee, Sally Lord, Ian Marschner, et al.

Future Oncology (London, England)|May 22, 2023

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.

JTO Clinical and Research Reports|September 22, 2025

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With <i>RET</i> Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup AnalysisKoichi Goto, Herbert H Loong, Caicun Zhou, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisChee Khoon Lee, Yi-Long Wu, Pei Ni Ding, et al.

Pageof 26

Showing results (111-120 of 259) with videos related to

Sort By:

Pageof 26

European Journal of Cancer (Oxford, England : 1990)|June 24, 2014

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trialJames Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, et al.

The Oncologist|May 17, 2017

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line GefitinibZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.

European Journal of Cancer (Oxford, England : 1990)|July 7, 2019

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patientsZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.

Cancer Treatment Reviews|January 3, 2026

Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Seng Wee Cheo, Molly S C Li, Derek De-Rui Huang, et al.

Science Translational Medicine|December 9, 2016

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastasesZhenfan Yang, Qiuli Guo, Yingchun Wang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2018

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung CancerChee Khoon Lee, Sally Lord, Ian Marschner, et al.

Future Oncology (London, England)|May 22, 2023

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.

JTO Clinical and Research Reports|September 22, 2025

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With <i>RET</i> Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup AnalysisKoichi Goto, Herbert H Loong, Caicun Zhou, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2018

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramSolange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisChee Khoon Lee, Yi-Long Wu, Pei Ni Ding, et al.

Pageof 26